Marpai, INC 8-K filings

Marpai, Inc. has announced the closing of a private placement, raising approximately $12.1 million through the sale of Series A Convertible Preferred Stock to accredited investors.

Marpai, Inc. announced debt restructuring agreements with JGB Capital and AXA S.A., reducing debt service by $26.4 million through 2027 and enhancing near-term liquidity.

Marpai, Inc. announced that CEO Damien Lamendola will assume the role of President following Dallas Scrip's resignation, effective January 30, 2026.

Marpai Inc. announced a private placement of common stock and warrants, raising approximately $350,000 for working capital and general corporate purposes.

Marpai, Inc. reports significant operational and financial improvements in Q3 2025, driven by cost discipline and strategic capital infusion, positioning for 2026 growth.

Marpai Inc. announced a private placement raising approximately $4 million through the issuance of common stock and warrants, with significant participation from company insiders.

Marpai Inc. has amended its Certificate of Incorporation to authorize 2,000,000 shares of blank-check preferred stock, granting its Board of Directors discretion over their terms.

Marpai Inc. announced a private placement of 147,058 Class A common shares to HillCour Investment Fund, an entity controlled by its CEO, Damien Lamendola, at $1.36 per share.

Marpai Inc. announced a private placement of Class A common stock, raising approximately $1.1 million, with significant participation from an entity controlled by its CEO.

Marpai, Inc. announced the immediate appointment of Dallas Scrip as President, following John Powers' resignation due to personal health reasons.

Marpai, Inc. stockholders approved the election of directors, ratification of auditors, and an amendment to authorize 2,000,000 shares of blank-check preferred stock at their 2025 Annual Meeting.

Marpai, Inc. reported significant reductions in operating and net losses for Q2 2025, driven by a 70% cut in operating expenses, as it targets profitability by Q1 2026.

Marpai, Inc. announced a private placement of Class A common stock, raising approximately $650,000, with significant participation from its CEO's controlled entity.

Marpai Inc. completed a private placement of 130,208 shares of Class A common stock at $1.152 per share, raising approximately $150,000, with a significant portion purchased by an entity controlled by its Chief Executive Officer.

Marpai Inc. announces its Q1 2025 financial results, highlighting a reduction in operating expenses and net loss despite a decrease in net revenues.

Marpai, Inc. appoints Dallas Scrip as Chief Operating Officer and President of MarpaiRx, effective June 2, 2025, to bolster leadership and drive profitable growth.

Marpai, Inc. announced its Q4 and full year 2024 financial results, highlighting a decrease in net revenues but significant improvements in operating expenses and net losses.

Marpai Inc. and AXA S.A. have agreed to reduce Marpai's debt by $3 million after Marpai met certain conditions, including a significant equity contribution from its largest shareholder and maintaining a stock exchange listing.

Marpai, Inc. has amended its securities purchase agreement to secure an additional $5 million in funding, with $2 million received upfront and $3 million held in escrow.

Marpai Inc. has successfully priced a private placement offering, raising approximately $700,000 through the issuance of common stock to an institutional fund and company insiders.

Marpai, Inc. announced its third quarter 2024 financial results, highlighting a reduction in operating expenses and losses despite a decrease in revenue.

Marpai Inc. has entered into a securities purchase agreement to issue over 2.7 million shares of its Class A common stock in a private placement, raising approximately $650,000.

Marpai's second quarter 2024 results show a decrease in revenue and a significant increase in operating loss, despite progress in operational performance.

Marpai Inc. has redeemed $5 million of its senior secured convertible debentures, reducing the total outstanding principal to $6.83 million.

Marpai, Inc. announced its decision to withdraw from the Nasdaq hearings process and transition its stock listing to the OTCQX market to reduce costs and focus on profitable growth.

Mike Dendy has resigned from the board of directors of Marpai, Inc., effective immediately, with no indication of disagreement with the company's operations or policies.

Marpai, Inc. announced its first quarter 2024 financial results, highlighting a substantial reduction in operating expenses and net loss despite a decrease in revenue.

Marpai Inc. held its 2024 Annual Meeting where stockholders approved the 2024 Global Stock Incentive Plan, elected directors, ratified the appointment of UHY LLP as auditor, and approved an amendment to the Certificate of Incorporation to include 2,000,000 shares of preferred stock.

Marpai, Inc. has entered into a securities purchase agreement for $11.83 million in senior secured convertible debentures, providing the company with $11 million in funding.

Marpai Inc. announced improved financial results for the fourth quarter and full year 2023, driven by the Maestro acquisition and corrective actions.